EP1003846A4 - Inhibiteurs de proteases - Google Patents

Inhibiteurs de proteases

Info

Publication number
EP1003846A4
EP1003846A4 EP98923299A EP98923299A EP1003846A4 EP 1003846 A4 EP1003846 A4 EP 1003846A4 EP 98923299 A EP98923299 A EP 98923299A EP 98923299 A EP98923299 A EP 98923299A EP 1003846 A4 EP1003846 A4 EP 1003846A4
Authority
EP
European Patent Office
Prior art keywords
protease inhibitors
protease
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98923299A
Other languages
German (de)
English (en)
Other versions
EP1003846A1 (fr
Inventor
Andrew D Gribble
Ashley Edward Fenwick
Robert W Marquis
Daniel F Veber
Jason Witherington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Publication of EP1003846A1 publication Critical patent/EP1003846A1/fr
Publication of EP1003846A4 publication Critical patent/EP1003846A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP98923299A 1997-05-06 1998-05-06 Inhibiteurs de proteases Withdrawn EP1003846A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4575897P 1997-05-06 1997-05-06
US45758P 1997-05-06
PCT/US1998/003200 WO1998050533A1 (fr) 1997-05-06 1998-05-06 Inhibiteurs de proteases

Publications (2)

Publication Number Publication Date
EP1003846A1 EP1003846A1 (fr) 2000-05-31
EP1003846A4 true EP1003846A4 (fr) 2002-11-13

Family

ID=21939723

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98923299A Withdrawn EP1003846A4 (fr) 1997-05-06 1998-05-06 Inhibiteurs de proteases

Country Status (19)

Country Link
EP (1) EP1003846A4 (fr)
JP (1) JP2001525804A (fr)
KR (1) KR20010012256A (fr)
CN (1) CN1255161A (fr)
AR (1) AR013079A1 (fr)
AU (1) AU7562598A (fr)
BR (1) BR9809306A (fr)
CA (1) CA2288868A1 (fr)
CO (1) CO4950618A1 (fr)
HU (1) HUP0002247A3 (fr)
IL (1) IL132088A0 (fr)
NO (1) NO995434D0 (fr)
NZ (1) NZ337889A (fr)
PE (1) PE71599A1 (fr)
PL (1) PL336856A1 (fr)
TR (1) TR199902766T2 (fr)
UY (1) UY25143A1 (fr)
WO (1) WO1998050533A1 (fr)
ZA (1) ZA983762B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5150165A1 (es) * 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
DZ3083A1 (fr) * 1999-02-19 2004-06-02 Smithkline Beecham Corp Composés nouveaux inhibiteurs de protéases, procédé pour leur préparation et compositions pharmaceutiques les conentant.
GB9911417D0 (en) * 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
JP2003513971A (ja) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
EP1326848A1 (fr) * 2000-10-19 2003-07-16 Naeja Pharmaceutical Inc. Derives de dihydropyrimidine utilises comme inhibiteurs de cysteine protease
IL155958A0 (en) * 2000-11-17 2003-12-23 Medivir Ab Cysteine protease inhibitors
WO2002040462A2 (fr) * 2000-11-17 2002-05-23 Medivir Uk Limited Inhibiteurs de cystéine protéase
IL156776A0 (en) * 2001-01-17 2004-02-08 Amura Therapeutics Ltd Inhibitors of cruzipain and other cysteine proteases
US7132449B2 (en) * 2001-01-17 2006-11-07 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
JP2004522738A (ja) * 2001-01-17 2004-07-29 アミュラ テラピューティクス リミテッド クルジパインおよび他のシステインプロテアーゼの阻害剤としての環状２−カルボニルアミノケトン
WO2002057270A1 (fr) * 2001-01-17 2002-07-25 Amura Therapeutics Limited Inhibiteurs de la cruzipaine et autres cysteines proteases
CA2463770A1 (fr) * 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes convenant comme inhibiteurs reversibles de proteases de la cysteine
WO2004007501A1 (fr) * 2002-07-16 2004-01-22 Amura Therapeutics Limited Composes a activite biologique
KR100962972B1 (ko) 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
AU2016206281B2 (en) * 2003-08-06 2017-11-30 Senomyx, Inc. Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
AR046078A1 (es) 2003-08-06 2005-11-23 Senomyx Inc Nuevos sabores, modificadores de sabores, sustancias gustativas, mejoradores de gusto, sustancias gustativas y/o mejoradoras del gusto umani o dulce y uso de los mismos.
AU2005203972B2 (en) 2004-01-08 2010-11-18 Medivir Ab Cysteine protease inhibitors
MX2008002363A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
CN101784516B (zh) * 2007-06-13 2014-07-02 百时美施贵宝公司 作为凝血因子抑制剂的二肽类似物
US7893067B2 (en) 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
EP2240491B1 (fr) 2008-01-09 2015-07-15 Amura Therapeutics Limited DÉRIVÉS DE TÉTRAHYDROFURO(2,3-b)PYRROL-3-ONE COMME INHIBITEURS DE CYSTÉINE PROTÉINASES
GB0817424D0 (en) * 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0525420A1 (fr) * 1991-07-01 1993-02-03 Mitsubishi Chemical Corporation Pseudopeptides et peptides caractérisés par une partie méthyle cétone substituée à la terminaison C comme inhibiteurs de thiol protéase
EP0543310A2 (fr) * 1991-11-19 1993-05-26 Suntory Limited Dérivés de dipeptide et agent prophylactique et thérapeutique les contenant pour maladies osseuses
EP0603873A1 (fr) * 1992-12-25 1994-06-29 Mitsubishi Chemical Corporation Dérivés d'aminocétone
EP0611756A2 (fr) * 1993-02-19 1994-08-24 Takeda Chemical Industries, Ltd. Alcool et aldéhyde dérivés comme inhibiteur de cathepsin L et comme inhibiteur de la résorption osseuse
EP0623627A1 (fr) * 1993-04-28 1994-11-09 Mitsubishi Chemical Corporation Dérivés de sulphonamide
WO1997016177A1 (fr) * 1995-10-30 1997-05-09 Smithkline Beecham Corporation Procede d'inhibition de la cathepsine k

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403952A (en) * 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
WO1998004539A1 (fr) * 1996-07-29 1998-02-05 Mitsubishi Chemical Corporation Derives heterocycliques oxygenes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0525420A1 (fr) * 1991-07-01 1993-02-03 Mitsubishi Chemical Corporation Pseudopeptides et peptides caractérisés par une partie méthyle cétone substituée à la terminaison C comme inhibiteurs de thiol protéase
EP0543310A2 (fr) * 1991-11-19 1993-05-26 Suntory Limited Dérivés de dipeptide et agent prophylactique et thérapeutique les contenant pour maladies osseuses
EP0603873A1 (fr) * 1992-12-25 1994-06-29 Mitsubishi Chemical Corporation Dérivés d'aminocétone
EP0611756A2 (fr) * 1993-02-19 1994-08-24 Takeda Chemical Industries, Ltd. Alcool et aldéhyde dérivés comme inhibiteur de cathepsin L et comme inhibiteur de la résorption osseuse
EP0623627A1 (fr) * 1993-04-28 1994-11-09 Mitsubishi Chemical Corporation Dérivés de sulphonamide
WO1997016177A1 (fr) * 1995-10-30 1997-05-09 Smithkline Beecham Corporation Procede d'inhibition de la cathepsine k

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. L. CONROY: "Synthesis of cyclohexanone-based Cathepsin B inhibitors that interact with both the S and S' binding sites", TETRAHEDRON LETTERS, vol. 39, 5 November 1998 (1998-11-05), pages 8253 - 8256, XP002211176 *
J. L. CONROY: "Using the electrostatic field effect to design a new class of inhibitors for cysteine proteases", J. AM. CHEM. SOC., vol. 119, 7 May 1997 (1997-05-07), pages 4285 - 4291, XP002211175 *
R. W. MARQUIS ET AL.: "Cyclic ketone inhibitors of the cysteine protease Cathepsin K", J. MED. CHEM., vol. 44, 2001, pages 725 - 736, XP002211174 *
See also references of WO9850533A1 *

Also Published As

Publication number Publication date
NO995434L (no) 1999-11-05
KR20010012256A (ko) 2001-02-15
BR9809306A (pt) 2000-07-04
HUP0002247A2 (hu) 2001-05-28
AU7562598A (en) 1998-11-27
CO4950618A1 (es) 2000-09-01
CA2288868A1 (fr) 1998-11-12
TR199902766T2 (xx) 2000-02-21
PL336856A1 (en) 2000-07-17
NO995434D0 (no) 1999-11-05
HUP0002247A3 (en) 2003-01-28
EP1003846A1 (fr) 2000-05-31
AR013079A1 (es) 2000-12-13
UY25143A1 (es) 1998-11-27
ZA983762B (en) 1998-11-06
JP2001525804A (ja) 2001-12-11
CN1255161A (zh) 2000-05-31
NZ337889A (en) 2001-09-28
PE71599A1 (es) 1999-09-15
WO1998050533A1 (fr) 1998-11-12
IL132088A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
IL131661A0 (en) Protease inhibitors
PL336589A1 (en) Serinic protease inhibitors
PL349192A1 (en) Protease inhibitors
ZA98376B (en) Sulfamide-metalloprotease inhibitors
EP0744948A4 (fr) Inhibiteurs de protease
PL328307A1 (en) Serinic protease inhibitors
GB2321641B (en) Sulfamide-metalloprotease inhibitors
IL132630A0 (en) Protease inhibitors
ZA983522B (en) Protease inhibitors
PL336856A1 (en) Protease inhibitors
EP1093367A4 (fr) Inhibiteurs de proteases
PL328875A1 (en) Serinic protease inhibitors
ZA988479B (en) Protease inhibitors
PL328223A1 (en) Aspartil protease inhibitors
EP1067894A4 (fr) Inhibiteurs de protease
EP1079821A4 (fr) Inhibiteurs de la protease
ZA988064B (en) Protease inhibitors
EP1086083A4 (fr) Inhibiteurs de proteases
EP1140897A4 (fr) Inhibiteurs de proteases
EP0975612A4 (fr) Inhibiteurs de proteases
ZA983097B (en) Protease inhibitors
ZA977032B (en) Protease inhibitors
HK1030414A (en) Protease inhibitors
HK1028258A (en) Protease inhibitors
HK1028786A (en) Protease inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 19991206

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

Owner name: SMITHKLINE BEECHAM CORPORATION

D17D Deferred search report published (deleted)

Owner name: SMITHKLINE BEECHAM PLC

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

Owner name: SMITHKLINE BEECHAM CORPORATION

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 9/99 A, 7C 12N 9/50 B, 7A 01N 43/02 B, 7A 01N 43/06 B, 7A 01N 43/08 B, 7A 01N 43/16 B, 7A 01N 43/18 B, 7A 61P 21/06 B, 7C 07D 407/12 B, 7C 07D 405/12 B, 7C 07D 409/12 B, 7C 07D 495/04 B, 7C 07D 309/14 B, 7C 07D 307/22 B, 7A 61K 31/34 B, 7A 61K 31/47 B, 7A 61K 31/44 B, 7A 61K 31/38 B, 7A 61K 31/445 B, 7A 61K 31/495 B, 7A 61K 31/415 B, 7A 61K 31/35 B, 7A 61K 31/40 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020930

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030624

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1028786

Country of ref document: HK